Brain Metastasis From Advanced-Stage Lung Carcinoma: Differentiating From Stroke and Exploring Treatment and Prevention Methods.

Metastasis is one of the most significant contributors to mortality and treatment-related morbidity in patients with advanced-stage lung cancer, as it is often considered incurable once discovered. Accordingly, a significant challenge with metastasis is identifying its progression early, as initial imaging may be negative while metastasis propagates undetected. Hence, there is a growing consensus that determining the optimal frequency and improving screening protocols for brain metastasis in patients with lung cancer are essential areas of research, as earlier detection could allow for prompt adjustments in treatment and/or prophylactic interventions, thereby potentially improving outcomes and reducing risks associated with more invasive procedures. Moreover, another difficulty in the diagnosis of brain metastasis can arise from its symptom overlap with strokes, often necessitating methods such as the use of the visual-aphasia-neglect assessment scale, as well as accounting for patient history and timeline of symptoms, with definitive diagnosis established through a head CT/MRI. This report presents a patient with a history of a tobacco use disorder, upper esophageal stricture, and a one-year history of advanced stage III non-small-cell lung carcinoma who reported to the emergency department (ED) with concerns of neurological weakness where multiple lesions with vasogenic edema were discovered on head CT, suggestive of brain metastasis. The patient was admitted to the hospital, where he was treated with dexamethasone and subsequent MRI confirmed the diagnosis of brain metastasis. He was discharged home to begin whole brain radiation therapy with orders to temporarily hold his chemotherapy medication. The patient initially responded well, but most recent CT scans have indicated progression of metastasis to bone and gastrointestinal organs. Thus, earlier recognition of impending brain metastasis, especially in advanced-stage lung carcinoma, is a significant area of research, as timely detection can have decisive impacts on patient outcomes and possible interventions.